To find out more about
our coverage in China
CLICK
HERE
Combine the strengths of...
CHINATROVE & DATAMONITOR
HEALTHCARE’S CHINA CHANNEL
to ensure your successful entrance into
the Type 2 Diabetes market in China
With Type 2 Diabetes prevalent cases on the rise, where is the best location to focus your
trial? Knowing the patient potential by city will help you focus target list.
Tianjin:
1,053,665
Beijing:
1,980,542
Shanghai:
2,516,320
Guangzhou:
1,357,129
Finding the Right Hospital:
If you want to set up a trial you need to know where the best sites are located. We’ve put
together the number of physicians by hospital tiers, and in CFDA certified hospitals who
are able to undertake your trial.
Physicians in 3A hospitals
35000
5000
4500
Physicians in 3A hospitals
30000
4000
25000
3500
20000
3000
2500
15000
2000
1500
10000
1000
5000
500
0
0
Beijing
Shanghai
Guangzhou
Physicians in CFDA Endocrinology Hospitals
Physicians in CFDA Endocrinology Hospitals
Tianjin
Placing your Trial:
Identifying hospitals with Type 2 diabetes trial experience, and understanding a hospital’s
current trial load will help inform where best to place your trial.
ActiveEndocrinology /
Diabetes Certifications
Hospitals with
Diabetes trials
Trial Count
7
6
51
BEIJING
9
8
56
SHANGHAI
1
1
1
GUANGZHOU
2
1
1
TIANJIN
Understanding the Demand:
China Sales Forecast by Drug Class ($ millions)
Understand the need for your drug in the Type 2 Diabetes market in China by studying the
market landscape and future dynamics.
70
60
50
GLP-1
SGLT-2
DPP-IV
40
30
20
10
0
2012
2013
2014
2015
Assess the commercial potential of your drug candidate in the rapidly evolving diabetes
treatment landscape, as new drugs and classes gain market share.
Potential Patient Share:
Use detailed patient-based forecasts to model potential patient share for your new drug
candidate by drug and drug class. Understand the factors that are driving or constraining
patient share and assess how these factors will impact your new drug.
2012
2013
2014
2015
GLP-1
10,411
patients
GLP-1
6,540
patients
GLP-1
12,137
DPP-IV
25,169
patients
patients
GLP-1
8,979
patients
SGLT-2
2,291
DPP-IV
40,255
patients
SGLT-2
5,677
patients
DPP-IV
52,489
patients
patients
DPP-IV
62,314
patients
To find out more about
our coverage in China
CLICK
HERE